600 related articles for article (PubMed ID: 35952457)
21. Is vaccine response to SARS-CoV-2 preserved after switching to anti-CD20 therapies in patients with multiple sclerosis or related disorders?
Jeantin L; Abdi B; Soulié C; Sterlin D; Maillart E; Beigneux Y; Hippolyte A; Belin L; Marcelin AG; Pourcher V; Louapre C
J Neurol Neurosurg Psychiatry; 2023 Dec; 95(1):19-28. PubMed ID: 37479463
[TBL] [Abstract][Full Text] [Related]
22. Multiple sclerosis therapies differentially affect SARS-CoV-2 vaccine-induced antibody and T cell immunity and function.
Sabatino JJ; Mittl K; Rowles WM; McPolin K; Rajan JV; Laurie MT; Zamecnik CR; Dandekar R; Alvarenga BD; Loudermilk RP; Gerungan C; Spencer CM; Sagan SA; Augusto DG; Alexander JR; DeRisi JL; Hollenbach JA; Wilson MR; Zamvil SS; Bove R
JCI Insight; 2022 Feb; 7(4):. PubMed ID: 35030101
[TBL] [Abstract][Full Text] [Related]
23. The impact of hybrid immunity on immune responses after SARS-CoV-2 vaccination in persons with multiple sclerosis treated with disease-modifying therapies.
Rabenstein M; Thomas OG; Carlin G; Khademi M; Högelin KA; Malmeström C; Axelsson M; Brandt AF; Gafvelin G; Grönlund H; Kockum I; Piehl F; Lycke J; Olsson T; Hessa T
Eur J Neurol; 2023 Dec; 30(12):3789-3798. PubMed ID: 37522464
[TBL] [Abstract][Full Text] [Related]
24. Interferon Beta-1a treatment promotes SARS-CoV-2 mRNA vaccine response in multiple sclerosis subjects.
Maniscalco GT; Manzo V; Ferrara AL; Perrella A; Di Battista M; Salvatore S; Graziano D; Viola A; Amato G; Moreggia O; Di Giulio Cesare D; Barbato S; Servillo G; Longo K; Di Giovanni M; Scarpati B; Muggianu SM; Longo G; Russo G; Andreone V; De Rosa V
Mult Scler Relat Disord; 2022 Feb; 58():103455. PubMed ID: 34929455
[TBL] [Abstract][Full Text] [Related]
25. Anti-CD20 therapies decrease humoral immune response to SARS-CoV-2 in patients with multiple sclerosis or neuromyelitis optica spectrum disorders.
Louapre C; Ibrahim M; Maillart E; Abdi B; Papeix C; Stankoff B; Dubessy AL; Bensa-Koscher C; Créange A; Chamekh Z; Lubetzki C; Marcelin AG; Corvol JC; Pourcher V;
J Neurol Neurosurg Psychiatry; 2022 Jan; 93(1):24-31. PubMed ID: 34341142
[TBL] [Abstract][Full Text] [Related]
26. NVX-CoV2373-induced T- and B-cellular immunity in immunosuppressed people with multiple sclerosis that failed to respond to mRNA and viral vector SARS-CoV-2 vaccines.
Mueller-Enz M; Woopen C; Katoul Al Rahbani G; Haase R; Dunsche M; Ziemssen T; Akgün K
Front Immunol; 2023; 14():1081933. PubMed ID: 37545513
[TBL] [Abstract][Full Text] [Related]
27. Humoral- and T-Cell-Specific Immune Responses to SARS-CoV-2 mRNA Vaccination in Patients With MS Using Different Disease-Modifying Therapies.
Tortorella C; Aiello A; Gasperini C; Agrati C; Castilletti C; Ruggieri S; Meschi S; Matusali G; Colavita F; Farroni C; Cuzzi G; Cimini E; Tartaglia E; Vanini V; Prosperini L; Haggiag S; Galgani S; Quartuccio ME; Salmi A; Repele F; Altera AMG; Cristofanelli F; D'Abramo A; Bevilacqua N; Corpolongo A; Puro V; Vaia F; Capobianchi MR; Ippolito G; Nicastri E; Goletti D;
Neurology; 2022 Feb; 98(5):e541-e554. PubMed ID: 34810244
[TBL] [Abstract][Full Text] [Related]
28. Risk of COVID-19 infection and severe disease in MS patients on different disease-modifying therapies.
Smith TE; Madhavan M; Gratch D; Patel A; Saha V; Sammarco C; Rimler Z; Zuniga G; Gragui D; Charvet L; Cutter G; Krupp L; Kister I; Ryerson LZ
Mult Scler Relat Disord; 2022 Apr; 60():103735. PubMed ID: 35398713
[TBL] [Abstract][Full Text] [Related]
29. Humoral and cellular responses to mRNA vaccines against SARS-CoV-2 in patients with a history of CD20 B-cell-depleting therapy (RituxiVac): an investigator-initiated, single-centre, open-label study.
Moor MB; Suter-Riniker F; Horn MP; Aeberli D; Amsler J; Möller B; Njue LM; Medri C; Angelillo-Scherrer A; Borradori L; Radonjic-Hoesli S; Seyed Jafari SM; Chan A; Hoepner R; Bacher VU; Mani LY; Iype JM; Hirzel C; Maurer B; Sidler D
Lancet Rheumatol; 2021 Nov; 3(11):e789-e797. PubMed ID: 34514436
[TBL] [Abstract][Full Text] [Related]
30. Strong T-cell activation in response to COVID-19 vaccination in multiple sclerosis patients receiving B-cell depleting therapies.
Alfonso-Dunn R; Lin J; Kirschner V; Lei J; Feuer G; Malin M; Liu J; Roche M; Sadiq SA
Front Immunol; 2022; 13():926318. PubMed ID: 35990701
[TBL] [Abstract][Full Text] [Related]
31. Recall response to COVID-19 antigen is preserved in people with multiple sclerosis on anti-CD20 medications - A pilot study.
Moser T; Otto F; O'Sullivan C; Hitzl W; Pilz G; Harrer A; Trinka E; Wipfler P
Mult Scler Relat Disord; 2022 Mar; 59():103560. PubMed ID: 35093840
[TBL] [Abstract][Full Text] [Related]
32. Immunogenicity and safety of mRNA COVID-19 vaccines in people with multiple sclerosis treated with different disease-modifying therapies.
Capone F; Lucchini M; Ferraro E; Bianco A; Rossi M; Cicia A; Cortese A; Cruciani A; De Arcangelis V; De Giglio L; Motolese F; Sancetta B; Mirabella M; Di Lazzaro V
Neurotherapeutics; 2022 Jan; 19(1):325-333. PubMed ID: 34859382
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of immunological responses to third COVID-19 vaccine among people treated with sphingosine receptor-1 modulators and anti-CD20 therapy.
Katz Sand I; Gnjatic S; Krammer F; Tuballes K; Carreño JM; Satyanarayan S; Filomena S; Staker E; Tcheou J; Miller A; Fabian M; Safi N; Nichols J; Patel J; Krieger S; Tankou S; Horng S; Klineova S; Beck E; Merad M; Lublin F
Mult Scler Relat Disord; 2023 Feb; 70():104486. PubMed ID: 36628884
[TBL] [Abstract][Full Text] [Related]
34. Cellular and humoral immune responses following SARS-CoV-2 mRNA vaccination in patients with multiple sclerosis on anti-CD20 therapy.
Apostolidis SA; Kakara M; Painter MM; Goel RR; Mathew D; Lenzi K; Rezk A; Patterson KR; Espinoza DA; Kadri JC; Markowitz DM; E Markowitz C; Mexhitaj I; Jacobs D; Babb A; Betts MR; Prak ETL; Weiskopf D; Grifoni A; Lundgreen KA; Gouma S; Sette A; Bates P; Hensley SE; Greenplate AR; Wherry EJ; Li R; Bar-Or A
Nat Med; 2021 Nov; 27(11):1990-2001. PubMed ID: 34522051
[TBL] [Abstract][Full Text] [Related]
35. A prospective study of cellular immune response to booster COVID-19 vaccination in multiple sclerosis patients treated with a broad spectrum of disease-modifying therapies.
Torres P; Sancho-Saldaña A; Gil Sánchez A; Peralta S; Solana MJ; Bakkioui S; González-Mingot C; Quibus L; Ruiz-Fernández E; San Pedro-Murillo E; Brieva L
J Neurol; 2023 May; 270(5):2380-2391. PubMed ID: 36933032
[TBL] [Abstract][Full Text] [Related]
36. Humoral and T-Cell Response to SARS-CoV-2 Vaccination in Patients With Multiple Sclerosis Treated With Ocrelizumab.
Brill L; Rechtman A; Zveik O; Haham N; Oiknine-Djian E; Wolf DG; Levin N; Raposo C; Vaknin-Dembinsky A
JAMA Neurol; 2021 Dec; 78(12):1510-1514. PubMed ID: 34554197
[TBL] [Abstract][Full Text] [Related]
37. Effect of disease-modifying treatments on antibody-mediated response to anti-COVID19 vaccination in people with multiple sclerosis.
Mariottini A; Bertozzi A; Marchi L; Di Cristinzi M; Mechi C; Barilaro A; Massacesi L; Repice AM
J Neurol; 2022 Jun; 269(6):2840-2847. PubMed ID: 35239006
[TBL] [Abstract][Full Text] [Related]
38. Response of COVID-19 vaccination in multiple sclerosis patients following disease-modifying therapies: A meta-analysis.
Wu X; Wang L; Shen L; Tang K
EBioMedicine; 2022 Jul; 81():104102. PubMed ID: 35759920
[TBL] [Abstract][Full Text] [Related]
39. SARS-CoV-2 serology among people with multiple sclerosis on disease-modifying therapies after BBIBP-CorV (Sinopharm) inactivated virus vaccination: Same story, different vaccine.
Etemadifar M; Sedaghat N; Nouri H; Lotfi N; Chitsaz A; Khorvash R; Zolfaghari H; Ghasemi Movaghar A; Pourabbas M; Salari M
Mult Scler Relat Disord; 2022 Jan; 57():103417. PubMed ID: 34875487
[TBL] [Abstract][Full Text] [Related]
40. Vaccine-breakthrough SARS-CoV-2 infections in people with multiple sclerosis and related conditions: An observational study by the New York COVID-19 Neuro-Immunology Consortium (NYCNIC-2).
Klineova S; Farber RS; DeAngelis T; Leung T; Smith T; Blanck R; Zhovtis-Ryerson L; Harel A
Mult Scler; 2023 Jul; 29(8):990-1000. PubMed ID: 37431628
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
